UK cell & gene therapy: From investment to impact. A fireside chat with Sam Goldsmith & Jim Faulkner @cellandgenetherapycatapult
UK cell & gene therapy: From investment to impact. A fireside chat with Sam Goldsmith & Jim Faulkner  @cellandgenetherapycatapult
Uploaded September 2026 | Updated November 2026, 1 day ago
What does it take to turn a promising cell and gene therapy idea into an investable company?

In this discussion, Sam Goldsmith, Head of Venture Creation at CGT Catapult, speaks with Dr Jim Faulkner, Chair of the Board at CGT Catapult, about the UK cell and gene therapy investment landscape.

They discuss the pre-seed journey, what investors look for in early-stage companies, the UK’s competitiveness in attracting investment, and the opportunities and challenges shaping the future of the sector.

Watch the full conversation for insights into the route from early innovation to investment and commercialisation.
UK cell & gene therapy: From investment to impact. A fireside chat with Sam Goldsmith & Jim FaulknerMeet Leoni Mahal, our Regulatory Affairs ManagerMeet Maria Shutova, Senior Commercialisation of Research & Investment Manager | In & out of the labHow can apprenticeships benefit employers in the advanced therapies industry?Meet Misbah Fayyaz, MS&T Scientist | In and out of the labBuilding the CGT Catapult Stevenage Manufacturing Innovation Centre - TimelapseATTC network event 2025: Interview with Matthew Durdy, Cell and Gene Therapy CatapultEmployee Spotlight: Maria Barreira, Lead Scientist - Technology Process InnovationAdvanced Therapies Apprenticeship Community explainedCell and Gene Therapy Catapult GMP Manufacturing Report 2024 HighlightsIntroducing the Cell and Gene Therapy CatapultCell and Gene Therapy Catapults Edinburgh office and laboratories
Cell and Gene Therapy Catapult |

UK cell & gene therapy: From investment to impact. A fireside chat with Sam Goldsmith & Jim Faulkner

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER